Gastrointestinal Diseases Market is expected to grow from USD 17.27 billion in 2016 and reach USD 19.79 billion in 2022, growing at a CAGR of 2.3% during the forecast period. Download Free Sample : https://www.scalarmarketresearch.com/request-sample.php?id=12

1. 1
Gastrointestinal Diseases Market, by Drug
Category, and Geography – Global
Opportunity Analysis and Industry
Forecast, 2014 – 2022
October 2016

2. 2
Table of Contents
1 Market Overview..................................................................................................................... 11
1.1 Definitions ....................................................................................................................... 11
1.2 Research Methodology .................................................................................................... 11
1.3 Market Segmentation ...................................................................................................... 12
2 Executive Summary ................................................................................................................. 14
2.1 Market Summary: Global Gastrointestinal Diseases Market ............................................. 14
2.1.1 Global Gastrointestinal Diseases Market Size (US$ million), By Drug Category (2016 vs.
2022) ................................................................................................................................. 15
2.1.2 Global Gastrointestinal Diseases Market Size (US$ million), By Geography (2016 vs.
2021) ................................................................................................................................. 15
3 Market Dynamics..................................................................................................................... 17
3.1 Drivers ............................................................................................................................. 17
3.2 Restraints......................................................................................................................... 17
3.3 Opportunities................................................................................................................... 17
3.4 Premium Industry Trends................................................................................................. 18
4 Industry Analysis...................................................................................................................... 19
4.1 Major Selling Drug Analysis .............................................................................................. 19
4.1.1 Global Gastrointestinal Diseases Market Size (US$ million), Major Selling Drug Analysis
(2015) ................................................................................................................................. 19
4.1.2 Nexium..................................................................................................................... 19
4.1.3 Losec/Prilosec .......................................................................................................... 20
4.1.4 Dexilant.................................................................................................................... 20
4.1.5 Lialda........................................................................................................................ 20
4.1.6 Entyvio ..................................................................................................................... 20
4.1.7 Emend...................................................................................................................... 21
4.1.8 Creon ....................................................................................................................... 21
4.2 Pipeline Analysis .............................................................................................................. 22
4.2.1 Global Gastrointestinal Diseases Market Size (US$ million), Pipeline Drug Analysis
(2014 – 2022) .......................................................................................................................... 22
4.2.2 BEKINDA (RHB-104).................................................................................................. 23
4.2.3 RHB-105 (H. pylori)................................................................................................... 23
SAM
PLE

3. 3
4.2.4 RHB 104 (GI/Inflammation) ...................................................................................... 23
4.2.5 Relamorelin.............................................................................................................. 23
4.2.6 Viberzi...................................................................................................................... 24
4.2.7 mAbs Stelara (ustekinumab)..................................................................................... 24
4.2.8 AMG-714.................................................................................................................. 24
4.3 Key event analysis............................................................................................................ 25
5 Global Gastrointestinal Diseases Market, by Drug Category ..................................................... 26
5.1 Overview.......................................................................................................................... 26
5.1.1 Global Gastrointestinal Diseases Market Share (%), By Drug Category, 2016 & 2022. 27
5.1.2 Global Gastrointestinal Diseases Market Size with Pipeline Drug Revenue (US$
million), By Drug Category (2014 – 2022) ................................................................................. 27
5.1.3 Global Gastrointestinal Diseases Market Size (US$ million), By Drug Category (2014 –
2022) ................................................................................................................................. 27
5.1.4 Global Gastrointestinal Diseases Market Size (US$ million), By Drug Category, 2016 &
2022 ................................................................................................................................. 28
5.2 Antacid & Anti-Ulcerant ................................................................................................... 29
5.2.1 Global Antacid & Anti-Ulcerant Market Size (US$ million), By Region (2014 – 2022) . 29
5.3 GIT Anti-inflammatory...................................................................................................... 29
5.3.1 Global GIT Anti-inflammatory Market Size (US$ million), By Region (2014 – 2022).... 29
5.4 Antiemetic ....................................................................................................................... 30
5.4.1 Global Antiemetic Market Size (US$ million), By Region (2014 – 2022) ..................... 30
5.5 Anti-diarrhoea.................................................................................................................. 30
5.5.1 Global Anti-diarrhoea Market Size (US$ million), By Region (2014 – 2022)................ 30
5.6 Other GIT Therapeutics .................................................................................................... 31
5.6.1 Global Other GIT Therapeutics Market Size (US$ million), By Region (2014 – 2022) .. 31
6 Global Gastrointestinal Diseases Market, by Geography .......................................................... 32
6.1 Overview.......................................................................................................................... 32
6.1.1 Global Gastrointestinal Diseases Market Share (%), By Geography, 2016 & 2021...... 32
6.1.2 Global Gastrointestinal Diseases Market Size (US$ million), By Geography (2014 –
2022) ................................................................................................................................. 33
6.1.3 Global Gastrointestinal Diseases Market Size (US$ million), By Geography, 2016 &
2022 ................................................................................................................................. 33
6.2 North America.................................................................................................................. 34
SAM
PLE

4. 4
6.2.1 North America Gastrointestinal Diseases Market Share (%), By Country, 2016 & 2021..
................................................................................................................................. 34
6.2.2 North America Gastrointestinal Diseases Market Size (US$ million), By Country (2014
– 2022) ................................................................................................................................. 35
6.2.3 North America Gastrointestinal Diseases Market Size (US$ million), By Country, 2016
& 2021 ................................................................................................................................. 35
6.2.3.1 U.S........................................................................................................................ 35
6.2.3.1.1 Gastrointestinal Diseases Market in U.S., Market Size (US$ million) and Y-o-Y
Growth (%)....................................................................................................................... 35
6.2.3.2 Canada ................................................................................................................. 36
6.2.3.2.1 Gastrointestinal Diseases Market in Canada, Market Size (US$ million) and Y-o-Y
Growth (%)....................................................................................................................... 36
6.2.4 North America Gastrointestinal Diseases Market Size (US$ million), By Drug Category
(2014 – 2022) .......................................................................................................................... 36
6.3 Europe ............................................................................................................................. 37
6.3.1 Europe Gastrointestinal Diseases Market Share (%), By Country, 2016 & 2022 ......... 37
6.3.2 Europe Gastrointestinal Diseases Market Size (US$ million), By Country (2014 – 2022).
................................................................................................................................. 37
6.3.3 Europe Gastrointestinal Diseases Market Size (US$ million), By Country, 2016 & 2021 .
................................................................................................................................. 38
6.3.3.1 Germany............................................................................................................... 38
6.3.3.1.1 Gastrointestinal Diseases Market in Germany, Market Size (US$ million) and Y-
o-Y Growth (%)................................................................................................................. 38
6.3.3.2 France .................................................................................................................. 39
6.3.3.2.1 Gastrointestinal Diseases Market in France, Market Size (US$ million) and Y-o-Y
Growth (%)....................................................................................................................... 39
6.3.3.3 Rest of the Europe................................................................................................ 39
6.3.3.3.1 Gastrointestinal Diseases Market in Rest of the Europe, Market Size (US$
million) and Y-o-Y Growth (%) .......................................................................................... 39
6.3.4 Europe Gastrointestinal Diseases Market Size (US$ million), By Drug Category (2014 –
2022) ................................................................................................................................. 39
6.4 Asia-Pacific....................................................................................................................... 40
6.4.1 Asia-Pacific Gastrointestinal Diseases Market Share (%), By Country, 2016 & 2022... 40
6.4.2 Asia-Pacific Gastrointestinal Diseases Market Size (US$ million), By Country (2014 –
2022) ................................................................................................................................. 41
SAM
PLE

5. 5
6.4.3 Asia-Pacific Gastrointestinal Diseases Market Size (US$ million), By Country, 2016 &
2022 ................................................................................................................................. 41
6.4.3.1 India..................................................................................................................... 41
6.4.3.1.1 Gastrointestinal Diseases Market in India, Market Size (US$ million) and Y-o-Y
Growth (%)....................................................................................................................... 41
6.4.3.2 China.................................................................................................................... 42
6.4.3.2.1 Gastrointestinal Diseases Market in China, Market Size (US$ million) and Y-o-Y
Growth (%)....................................................................................................................... 42
6.4.3.3 Rest of the Asia-Pacific.......................................................................................... 42
6.4.3.3.1 Gastrointestinal Diseases Market in Rest of the Asia-Pacific, Market Size (US$
million) and Y-o-Y Growth (%) .......................................................................................... 42
6.4.4 Asia-Pacific Gastrointestinal Diseases Market Size (US$ million), By Drug Category
(2014 – 2022) .......................................................................................................................... 42
6.5 Rest of the World............................................................................................................. 43
6.5.1 Rest of the World Gastrointestinal Diseases Market Share (%), By Country, 2016 &
2021 ................................................................................................................................. 43
6.5.2 Rest of the World Gastrointestinal Diseases Market Size (US$ million), By Country
(2014 – 2022) .......................................................................................................................... 44
6.5.3 Rest of the World Gastrointestinal Diseases Market Size (US$ million), By Country,
2016 & 2021............................................................................................................................ 44
6.5.3.1 Latin America........................................................................................................ 44
6.5.3.1.1 Gastrointestinal Diseases Market in Latin America, Market Size (US$ million)
and Y-o-Y Growth (%)....................................................................................................... 44
6.5.3.2 Middle East and Africa.......................................................................................... 45
6.5.3.2.1 Gastrointestinal Diseases Market in Middle East and Africa, Market Size (US$
million) and Y-o-Y Growth (%) .......................................................................................... 45
6.5.4 Rest of the World Gastrointestinal Diseases Market Size (US$ million), By Drug
Category (2014 – 2022)............................................................................................................ 45
7 Competitive Landscape............................................................................................................ 46
7.1 Market Share Analysis...................................................................................................... 46
7.2 Key Innovators ................................................................................................................. 46
7.2.1 RedHill...................................................................................................................... 46
7.2.2 Allergan.................................................................................................................... 47
7.2.3 Shire......................................................................................................................... 47
8 Company Profiles..................................................................................................................... 48
SAM
PLE

6. 6
8.1 AstraZeneca..................................................................................................................... 48
8.1.1 Overview.................................................................................................................. 48
8.1.2 Key Strategies........................................................................................................... 48
8.1.2.1 Strong research and development activities ......................................................... 48
8.1.2.2 Novel therapeutics in company’s product offering................................................ 48
8.1.3 Recent Developments .............................................................................................. 49
8.2 Valeant (Salix Pharmaceuticals)........................................................................................ 50
8.2.1 Overview.................................................................................................................. 50
8.2.2 Key Strategies........................................................................................................... 50
8.2.2.1 Strategic merger and acquisitions......................................................................... 50
8.2.2.2 US FDA approvals ................................................................................................. 50
8.2.2.3 Strong positioning in gastrointestinal anti-inflammatory therapeutic segment ..... 51
8.2.3 Recent Developments .............................................................................................. 51
8.3 Takeda Pharmaceutical Company Limited ........................................................................ 52
8.3.1 Overview.................................................................................................................. 52
8.3.2 Key Strategies........................................................................................................... 52
8.3.2.1 Conducting awareness programs.......................................................................... 52
8.3.2.2 US FDA approval................................................................................................... 52
8.3.2.3 Expansion of product portfolio through acquisitions............................................. 53
8.3.2.4 Focus on core geography markets......................................................................... 53
8.3.3 Recent Developments .............................................................................................. 53
8.4 Shire ................................................................................................................................ 54
8.4.1 Overview.................................................................................................................. 54
8.4.2 Key Strategy ............................................................................................................. 54
8.4.2.1 Expansion through strategic acquisition................................................................ 54
8.4.2.2 Focus on the development of therapeutics for rare diseases................................. 54
8.4.2.3 Expansion of product portfolio through innovation............................................... 54
8.4.3 Recent Developments .............................................................................................. 55
8.5 Johnson & Johnson Private Limited .................................................................................. 56
8.5.1 Overview.................................................................................................................. 56
8.5.2 Key Strategy ............................................................................................................. 56
SAM
PLE

7. 7
8.5.2.1 Focus on product development and regulatory approvals..................................... 56
8.5.3 Recent Developments .............................................................................................. 56
8.6 Eisai Co., Ltd..................................................................................................................... 58
8.6.1 Overview.................................................................................................................. 58
8.6.2 Key Strategy ............................................................................................................. 58
8.6.2.1 Pricing strategy to emphasize affordability ........................................................... 58
8.6.2.2 Focus on emerging market.................................................................................... 58
8.6.2.3 Transformation of product portfolio ..................................................................... 58
8.6.3 Recent Developments .............................................................................................. 59
8.7 Allergan ........................................................................................................................... 60
8.7.1 Overview.................................................................................................................. 60
8.7.2 Key Strategies........................................................................................................... 60
8.7.2.1 Strategic merger and acquisitions......................................................................... 60
8.7.3 Recent Developments .............................................................................................. 60
9 Scalar 360 Degree Market Perspective..................................................................................... 61
9.1 Global Gastrointestinal Diseases Market Trend ................................................................ 61
10 Appendix ................................................................................................................................. 62
10.1 Acronyms......................................................................................................................... 62
SAM
PLE

8. 8
List of Tables
Table 1. Definitions.................................................................................................................... 11
Table 2. Market Summary: Global Gastrointestinal Diseases Market.......................................... 14
Table 3. Global Gastrointestinal Diseases Market Drivers........................................................... 17
Table 4. Global Gastrointestinal Diseases Market Restraints...................................................... 17
Table 5. Global Gastrointestinal Diseases Market Size (US$ million), Major Selling Drug Analysis
(2015) .................................................................................................................................... 19
Table 6. Global Gastrointestinal Diseases Market Size (US$ million), Pipeline Drug Analysis (2014
– 2022) .................................................................................................................................... 22
Table 7. Key event analysis- Global Gastrointestinal Diseases Market........................................ 25
Table 8. Global Gastrointestinal Diseases Market Size with Pipeline Drug Revenue (US$ million),
By Drug Category (2014 – 2022) ...................................................................................................... 27
Table 9. Global Gastrointestinal Diseases Market Size (US$ million), By Drug Category (2014 –
2022) .................................................................................................................................... 27
Table 10. Global Antacid & Anti-Ulcerant Market Size (US$ million), By Region (2014 – 2022) ..... 29
Table 11. Global GIT Anti-inflammatory Market Size (US$ million), By Region (2014 – 2022)........ 29
Table 12. Global Antiemetic Market Size (US$ million), By Region (2014 – 2022) ......................... 30
Table 13. Global Anti-diarrhoea Market Size (US$ million), By Region (2014 – 2022).................... 30
Table 14. Global Other GIT Therapeutics Market Size (US$ million), By Region (2014 – 2022) ...... 31
Table 15. Global Gastrointestinal Diseases Market Size (US$ million), By Geography (2014 – 2022).
.................................................................................................................................... 33
Table 16. North America Gastrointestinal Diseases Market Size (US$ million), By Country (2014 –
2022) .................................................................................................................................... 35
Table 17. Gastrointestinal Diseases Market in U.S., Market Size (US$ million) and Y-o-Y Growth (%)
.................................................................................................................................... 36
Table 18. Gastrointestinal Diseases Market in Rest of Canada, Market Size (US$ million) and Y-o-Y
Growth (%) .................................................................................................................................... 36
Table 19. North America Gastrointestinal Diseases Market Size (US$ million), By Drug Category
(2014 – 2022) .................................................................................................................................. 36
Table 20. Europe Gastrointestinal Diseases Market Size (US$ million), By Country (2014 – 2022) 38
Table 21. Gastrointestinal Diseases Market in Germany, Market Size (US$ million) and Y-o-Y
Growth (%) .................................................................................................................................... 38
Table 22. Gastrointestinal Diseases Market in France, Market Size (US$ million) and Y-o-Y Growth
(%) .................................................................................................................................... 39
SAM
PLE

9. 9
Table 23. Gastrointestinal Diseases Market in Rest of the Europe, Market Size (US$ million) and Y-
o-Y Growth (%)................................................................................................................................ 39
Table 24. Europe Gastrointestinal Diseases Market Size (US$ million), By Drug Category (2014 –
2022) .................................................................................................................................... 39
Table 25. Asia-Pacific Gastrointestinal Diseases Market Size (US$ million), By Country (2014 –
2022) .................................................................................................................................... 41
Table 26. Gastrointestinal Diseases Market in India, Market Size (US$ million) and Y-o-Y Growth
(%) .................................................................................................................................... 42
Table 27. Gastrointestinal Diseases Market in China, Market Size (US$ million) and Y-o-Y Growth
(%) 42
Table 28. Gastrointestinal Diseases Market in Rest of the Asia-Pacific, Market Size (US$ million)
and Y-o-Y Growth (%) ...................................................................................................................... 42
Table 29. Asia-Pacific Gastrointestinal Diseases Market Size (US$ million), By Drug Category (2014
– 2022) 42
Table 30. Rest of the World Gastrointestinal Diseases Market Size (US$ million), By Country (2014
– 2022) 44
Table 31. Gastrointestinal Diseases Market in Latin America, Market Size (US$ million) and Y-o-Y
Growth (%) 45
Table 32. Gastrointestinal Diseases Market in Middle East and Africa, Market Size (US$ million)
and Y-o-Y Growth (%) ...................................................................................................................... 45
Table 33. Rest of the World Gastrointestinal Diseases Market Size (US$ million), By Drug Category
(2014 – 2022) .................................................................................................................................. 45
Table 34. AstraZeneca – Company Overview ............................................................................... 48
Table 35. Valeant – Company Overview....................................................................................... 50
Table 36. Takeda Pharmaceutical Company Limited – Company Overview................................... 52
Table 37. Shire – Company Overview........................................................................................... 54
Table 38. Johnson & Johnson Private Limited – Company Overview ............................................ 56
Table 39. Eisai Co., Ltd. – Company Overview.............................................................................. 58
Table 40. Allergan– Company Overview....................................................................................... 60
Table 41. Global Gastrointestinal Diseases Market Trend ............................................................ 61
Table 42. List of Acronyms........................................................................................................... 62
SAM
PLE

10. 10
List of Figures
Figure 1. Research Methodology................................................................................................. 12
Figure 2. Gastrointestinal Diseases Market, By Drug Category..................................................... 12
Figure 3. Gastrointestinal Diseases Market, By Geography.......................................................... 13
Figure 4. Global Gastrointestinal Diseases Market Size (US$ million), By Drug Category (2016 vs.
2022) 15
Figure 5. Global Gastrointestinal Diseases Market Size (US$ million), By Geography (2016 vs.
2021) 15
Figure 6. Global Gastrointestinal Diseases Market Share (%), By Drug Category, 2016 & 2022 .... 27
Figure 7. Global Gastrointestinal Diseases Market Size (US$ million), By Drug Category, 2016 &
2022 28
Figure 8. Global Gastrointestinal Diseases Market Share (%), By Geography, 2016 & 2021.......... 32
Figure 9. Global Gastrointestinal Diseases Market Size (US$ million), By Geography, 2016 & 2022
33
Figure 10. North America Gastrointestinal Diseases Market Share (%), By Country, 2016 & 2021
34
Figure 11. North America Gastrointestinal Diseases Market Size (US$ illion), By Country, 2016 &
2021 35
Figure 12. Europe Gastrointestinal Diseases Market Share (%), By Country, 2016 & 2022 ......... 37
Figure 13. Europe Gastrointestinal Diseases Market Size (US$ million), By Country, 2016 & 2022
38
Figure 14. Asia-Pacific Gastrointestinal Diseases Market Share (%), By Country, 2016 & 2022... 40
Figure 15. Asia-Pacific Gastrointestinal Diseases Market Size (US$ million), By Country, 2016 &
2022 41
Figure 16. Rest of the World Gastrointestinal Diseases Market Share (%), By Country, 2016 &
2021 43
Figure 17. Rest of the World Gastrointestinal Diseases Market Size (US$ million), By Country,
2016 & 2021 44
Figure 18. Market Share Analysis of Key Players........................................................................ 46
SAM
PLE

11. 11
1 Market Overview
1.1 Definitions
Table 1. Definitions
Segment Drugs
Antacid & Anti-Ulcerant
Losec/Prilosec, Nexium, Protonix, Dexilant, Prevacid, Takepron,
Pentozol, Pariet/Aciphex, Carafate/Sulcrate, Cytotec, and Selbex
GIT Anti-inflammatory
Lialda, Delzicol, Asacol, Pentasa, Uceris, Apriso, Entyvio, Simponi
/Simponi Aria, and Remicade
Antiemetic Agent Emend, Aloxi, Kytril and others
Anti-diarrhoea Agent Enterogermina, Smecta, Imodium, Bioflor, Seirogan A and others
Other GIT Therapeutics
Creon, Donnatal, Daikenchuto, Bifico, Linzess (US)/Constella, and
others
Pipeline Drugs
BEKINDA (RHB-102), RHB-105 (H. pylori), RHB 104, Relamorelin, Viberzi,
mAbs Stelara (ustekinumab) and AMG-714
Source: Scalar Market Research Analysis
1.2 Research Methodology
The research methodology for market research reports at Scalar Market Research
includes a combination of top-down and bottom-up research formats. Continuous
market tracking, rigorous fact-checking, data-triangulation, and multiple layers of
quality control ensure high quality data that can be leveraged for actionable insights.
The global market for gastrointestinal diseases involves the study of different
branded and generic gastrointestinal therapeutics. The 'Global Gastrointestinal
Diseases Market – Industry Analysis, Market Size and Forecast (2014–2022)' report
includes market size and forecast, estimated from the period 2016 to 2022. This
report encompasses a detailed study for various gastrointestinal therapeutic used for
the treatment of conditions such as ulcerative colitis, irritable bowel diseases, celiac
diseases, and many others.
Drug category segment is primarily categorized into Antacid & Anti-Ulcerant, GIT
Anti-inflammatory, Antiemetic Agent, Anti-diarrhoea Agent and Other GIT
Therapeutics. The market size and forecast for each drug category type has been
SAM
PLE

12. 12
provided for the period 2014 to 2022, considering 2014 and 2015 as the base year.
The report also provides the compounded annual growth rate and due to (% CAGR)
for the forecast period 2016 to 2022 for each drug category.
Based on Geography, the market is segmented as North America, Europe, Asia-
Pacific and Rest of the World (RoW). The market size and forecast for geography
has been estimated for the period 2014 to 2022 in terms of revenue (US$ million).
The report also estimates the compounded annual growth rate (CAGR %) during the
forecast period from 2016 to 2022 for all the geographies mentioned above.
Figure 1. Research Methodology
Source: Scalar Market Research Analysis
1.3 Market Segmentation
Figure 2. Gastrointestinal Diseases Market, By Drug Category
Source: Scalar Market Research Analysis
Global
Market
Size
Market-specific
Revenuesof Key Market
Players
Revenuesof Key Market Players
GlobalMarket
Size
Segment-specific
MarketSize
Regional
Market
Size
Bottom-up
Top-down
SAM
PLE

13. 13
Figure 3. Gastrointestinal Diseases Market, By Geography
Source: Scalar Market Research Analysis
SAM
PLE

14. 14
2 Executive Summary
The global gastrointestinal diseases market was estimated to be US$XX million in
2016. This market is expected to grow at a CAGR of XX% in the forecast period and
is expected to be US$XX billion in 2022. This report segments the global
gastrointestinal diseases market by drug category and geography.
2.1 Market Summary: Global Gastrointestinal Diseases Market
Table 2. Market Summary: Global Gastrointestinal Diseases Market
Factors 2016 2022
Global Gastrointestinal Diseases
Market (US$ million)
17,271.2 14,859.7
Largest Revenue Generating
Market, by Drug Category (US$
million)
Lowest Revenue Generating
Market, by Drug Category (US$
million)
Segment with Highest Growth
Rate, by Drug Category
Largest Revenue Generating
Market, by Geography (US$
million)
Lowest Revenue Generating
Market, by Geography (US$
million)
Segment with Highest Growth
Rate, by Geography
Key Market Players (2015)
Pipeline Drugs
Source: Scalar Market Research analysis
SAM
PLE

15. 15
2.1.1 Global Gastrointestinal Diseases Market Size (US$ million), By Drug
Category (2016 vs. 2022)
Figure 4. Global Gastrointestinal Diseases Market Size (US$ million), By Drug
Category (2016 vs. 2022)
Source: Scalar Market Research analysis
Of the different drug category, antacid & anti-ulcerant accounted for the largest share
of the global market revenue. Growth of this segment is majorly attributed to the
approval of novel proton pump inhibitors by government regulatory. In addition,
growing demand for gastrointestinal therapeutics such as Nexium, Dexilant, and
Sulcrate in developing as developed countries drives the market growth of this
segment. However, anti-diarrohea segment recorded around 3.5% share of the
global market and is expected lose its market share during the forecast period owing
to the generic drug entry.
2.1.2 Global Gastrointestinal Diseases Market Size (US$ million), By
Geography (2016 vs. 2022)
Figure 5. Global Gastrointestinal Diseases Market Size (US$ million), By Geography
(2016 vs. 2022)
45.2%
26.7%
12.5%
3.6%
12.0%
2016
40.7%
38.6%
8.2%
2.4%
10.1%
2022
Antacid & Anti-
Ulcerant
GIT Anti-
inflamatory
Antiemetic
Agent
Anti-diarrhoea
Agent
Other GIT
Therapeutics
SAM
PLE

16. 17
3 Market Dynamics
3.1 Drivers
Table 3. Global Gastrointestinal Diseases Market Drivers
Drivers 2014-16 2017- 19 2020-22
● ● ●
◕ ◕ ●
◑ ● ●
Source: Scalar Market Research Analysis
Note: ●= Very High Impact, ◕= High Impact, ◑= Medium Impact, ◔= Low Impact
3.2 Restraints
Table 4. Global Gastrointestinal Diseases Market Restraints
Restraints 2014-16 2017- 19 2020-22
◑ ● ◕
◕ ◑ ◑
Source: Scalar Market Research Analysis
Note: ●= Very High Impact, ◕= High Impact, ◑= Medium Impact, ◔= Low Impact
3.3 Opportunities
 Development of biologic therapeutics for the treatment of gastrointestinal
diseases due to its favorable safety profile
 Development of monoclonal antibody related gastrointestinal therapeutics
 Increasing investment in emerging market of Asia-Pacific
SAM
PLE

17. 18
3.4 Premium Industry Trends
 Companies focusing on Irritable Bowel Diseases with Diarrhoea therapeutics
will serve as potential market to record high growth profit
SAM
PLE

18. 26
5 Global Gastrointestinal Diseases Market, by Drug Category
5.1 Overview
The global gastrointestinal diseases market is categorized into different types of drug
category such as Antacid & Anti-Ulcerant, GIT Anti-inflammatory, Antiemetic, Anti-
diarrhoea, and other GIT Therapeutics. This chapter analyzes the market revenue
generated by the different branded and generic therapeutics falls under different
drug categories. Antacid and Anti-Ulcerant section covers the study of variety of
Omeprazole drugs such as Losec/Prilosec, Nexium, Protonix, Dexilant, Prevacid,
Takepron, Pentozol, Pariet/Aciphex, and drugs such as Sucralfate
(Carafate/Sulcrate) , Cytotec and others. Companies such as AstraZeneca, Takeda
Pharmaceuticals and Daichi Sankyo are aggressively investing in research and
development activities to develop new anti-ulcerant moieties which help this segment
to grow during the forecast period. However, negative growth of the segment is
majorly attributed to the patent expiry of AstraZeneca’s two brand drug,
Losec/Prilosec and Nexium. On other side, the demand for Takeda Pharmaceutical’s
proton pump inhibitor (Dexilant) is increasing due to its unique mechanism of action
which is considered as positive impact for the growth of this segment.
GIT Anti-inflammatory comprises drugs such as Lialda, Delzicol, Asacol, Pentasa,
Uceris, Apriso, Entyvio, Remicade, and others. This segment is anticipated to growth
with the positive growth rate of XX% during the forecast year 2016 to 2022. The
growth of the segment is majorly supported by the launch of Takeda’s vedolizumab
category of drug (Entyvio). This monoclonal antibody based Anti-inflammatory drug
is expected to hit the market with highest growth rate due to its high efficacy for the
treatment of gastrointestinal diseases. Additionally, drug molecules such as Lialda
(Shire, Inc.) and Apriso (Salix Pharmaceutical) is also projected to support the
growth of this market segment owing to the patent exclusivity.
Antiemetic drug agents include the market estimation covering brand or generic
drugs such as Emend, Aloxi, Kytril and many others. Study for the gastrointestinal
drugs such as Enterogermina, Smecta, Imodium, and others are covered under the
anti-diarrhoea drug segment. While, Other GIT Therapeutics includes the revenue
generation of therapeutics such as Donnatal, Creon, Daikenchuto,
Linzess/Constella, and many others.
SAM
PLE

19. 27
5.1.1 Global Gastrointestinal Diseases Market Share (%), By Drug Category,
2016 & 2022
Figure 6. Global Gastrointestinal Diseases Market Share (%), By Drug Category, 2016
& 2022
Source: Scalar Market Research Analysis
5.1.2 Global Gastrointestinal Diseases Market Size with Pipeline Drug
Revenue (US$ million), By Drug Category (2014 – 2022)
Table 8. Global Gastrointestinal Diseases Market Size with Pipeline Drug Revenue
(US$ million), By Drug Category (2014 – 2022)
Drug 2014 2015 2016 2017 2018 2019 2020 2021 2022
CAGR%
(2016 –
2022)
Global
Commercialize
Drug Revenue
Global Pipeline
Drug Revenue
74.5%
Total
Source: Scalar Market Research Analysis
5.1.3 Global Gastrointestinal Diseases Market Size (US$ million), By Drug
Category (2014 – 2022)
Table 9. Global Gastrointestinal Diseases Market Size (US$ million), By Drug
Category(2014 – 2022)
Drug
Category
2014 2015 2016 2017 2018 2019 2020 2021 2022
CAGR%
(2016 –
2022)
45.2%
26.7%
12.5%
3.6%
12.0%
2016
40.7%
38.6%
8.2%
2.4%
10.1%
2022
Antacid & Anti-
Ulcerant
GIT Anti-
inflamatory
Antiemetic
Agent
Anti-diarrhoea
Agent
Other GIT
Therapeutics
SAM
PLE

20. 28
Antacid &
Anti-Ulcerant
GIT Anti-
inflammatory
Antiemetic
Anti-
diarrhoea
642.2
Other GIT
Therapeutics
Total
Source: Scalar Market Research Analysis
5.1.4 Global Gastrointestinal Diseases Market Size (US$ million), By Drug
Category, 2016 & 2022
Figure 7. Global Gastrointestinal Diseases Market Size (US$ million), By Drug
Category, 2016 & 2022
Source: Scalar Market Research Analysis
7,798.4
4,619.0
2,152.0
621.2
2,080.6
6,045.6
5,729.9
1,215.8
363.0
1,505.5
Antacid& Anti-
Ulcerant
GIT Anti-inflamatory Antiemetic Agent Anti-diarrhoea Agent Other GIT
Therapeutics
US$million
2016 2022
SAM
PLE

21. 29
5.2 Antacid & Anti-Ulcerant
5.2.1 Global Antacid & Anti-Ulcerant Market Size (US$ million), By Region
(2014 – 2022)
Table 10. Global Antacid & Anti-Ulcerant Market Size (US$ million), By Region (2014
– 2022)
Regions 2014 2015 2016 2017 2018 2019 2020 2021 2022
CAGR%
(2016 –
2022)
North
America
Europe
Asia-Pacific
Rest of the
World
442.8
Total
Source: Scalar Market Research Analysis
5.3 GIT Anti-inflammatory
5.3.1 Global GIT Anti-inflammatory Market Size (US$ million), By Region (2014
– 2022)
Table 11. Global GIT Anti-inflammatory Market Size (US$ million), By Region (2014 –
2022)
Regions 2014 2015 2016 2017 2018 2019 2020 2021 2022
CAGR%
(2016 –
2022)
North
America
Europe
Asia-Pacific
Rest of the
World
Total 3.7%
Source: Scalar Market Research Analysis
SAM
PLE

22. 32
6 Global Gastrointestinal Diseases Market, by Geography
6.1 Overview
The global gastrointestinal diseases market, by geography is categorized into North
America, Europe, Asia-Pacific, and Rest of the World. This chapter analyzed the
revenue generation by each region in terms of US$ million. The global market for
gastrointestinal diseases is majorly dominated by the developed regions of North
America and Europe which captured almost XX% share of the global market revenue
in 2016. Growth of this region is majorly attributed to the rising approval of novel
gastrointestinal therapeutics coupled with growing incidence of various
gastrointestinal diseases. Among which, North America is accounted for XX% share
of the total revenue in 2016. Approval of GIT Anti-inflammatory such as Lialda and
Entyvio helped the region to grow with steady growth rate during the forecast period.
However, increasing incidence of gastrointestinal diseases such as irritable bowel
syndrome and ulcerative colitis in Asia-Pacific and Rest of the World region drives
the growth of the market during the future period.
6.1.1 Global Gastrointestinal Diseases Market Share (%), By Geography, 2016
& 2022
Figure 8. Global Gastrointestinal Diseases Market Share (%), By Geography, 2016 &
2022
Source: Scalar Market Research Analysis
50.6%
35.9%
9.5%
4.0%
2016
50.5%
36.4%
9.4%
3.6%
2022
North America
Europe
Asia
Rest of the
World
SAM
PLE

23. 33
6.1.2 Global Gastrointestinal Diseases Market Size (US$ million), By
Geography (2014 – 2022)
Table 15. Global Gastrointestinal Diseases Market Size (US$ million), By
Geography(2014 – 2022)
Geography 2014 2015 2016 2017 2018 2019 2020 2021 2022
CAGR%
(2016 –
2022)
North
America
Europe
Asia-Pacific
Rest of the
World
761.1
Total
Source: Scalar Market Research Analysis
6.1.3 Global Gastrointestinal Diseases Market Size (US$ million), By
Geography, 2016 & 2022
Figure 9. Global Gastrointestinal Diseases Market Size (US$ million), By Geography,
2016 & 2022
Source: Scalar Market Research Analysis
8,745.8
6,205.5
1,635.2
684.8
7,511.1
5,411.3
1,401.6
535.7
NorthAmerica Europe Asia Rest of the World
US$million
2016 2022
SAM
PLE

24. 34
6.2 North America
North America recorded US$ XX million revenue, around 50.64% share of the global
gastrointestinal diseases market. Gastrointestinal diseases market in North America
is majorly supported by the favorable government initiatives to introduce novel GIT
therapeutics. For example, in May 2014, U.S. FDA approved Takeda
Pharmaceuticals’ GIT Anti-inflammatory therapeutic, Entyvio. The drug is indicated
for the treatment of severe ulcerative colitis and moderate to severe Crohn‘s
disease. Takeda Pharmaceutical is projecting high sales growth of this integrin
receptor antagonist in the U.S. market owing to its proven safety and efficacy in
clinical trials for the treatment of ulcerative colitis and Crohn‘s disease. Additionally,
in November 2013, the U.S. Centers for Disease Control and Prevention estimated
that more than 21 million people in the U.S. get infected with noro-virus and develop
acute gastroenteritis each year which further stimulated the demand for GIT
therapeutics. However, patent expiry of blockbuster gastrointestinal therapeutics
such as Nexium, Pariet/Aciphex and many others adversely affected the growth of
the market.
6.2.1 North America Gastrointestinal Diseases Market Share (%), By Country,
2016 & 2022
Figure 10. North America Gastrointestinal Diseases Market Share (%), By Country,
2016 & 2022
Source: Scalar Market Research Analysis
87.1%
12.9%
2016
84.1%
15.9%
2022
U.S.
Canada
SAM
PLE

25. 46
7 Competitive Landscape
7.1 Market Share Analysis
Figure 18. Market Share Analysis of Key Players
Source: Annual Reports, Press Releases & Scalar Market Research analysis
7.2 Key Innovators
7.2.1 RedHill
RedHill is an emerging biopharmaceutical company, primarily focused on
commercialize and development of molecules for the treatment of gastrointestinal
and inflammatory diseases. This company is considered as one of the growing
company owing to the impressive late-stage clinical pipeline drugs for
gastrointestinal diseases. The company investigates gastrointestinal therapeutics
namely Bekinda, RHB-105 and RHB-104 under the phase - 3 clinical study which is
expected to hit the market in between 2018 - 2019. Among which, Bekinda contains
Ondansetron drug, filed for the antiemetic indication. The drug is primarily used to
prevent radiation-induced nausea and vomiting. Additionally, the company has
initiated a Phase - 2 clinical study with Bekinda for the treatment of Irritable bowel
syndrome with diarrhoea. Furthermore, the company is also investigating
therapeutics for the treatment of H. pylori infection (RHB-105) and Crohn’s disease
(RHB-104). Thus, it looks that the company have very interesting market potential to
8.3%
15.0%
12.6%
3.6%
5.0%
55.4%
Market Share (Value %), 2015 Allergan
AstraZeneca
Takeda
Pharmaceutical
Company Limited
Daichi Sankyo
Eisai Co., Ltd.
Other
SAM
PLE

26. 48
8 Company Profiles
8.1 AstraZeneca
8.1.1 Overview
Table 34. AstraZeneca – Company Overview
AstraZeneca - Company Detail
Headquarters London, UK
Year of Establishment 1999
No. of Employees (2015) More than 50,000
Gastrointestinal Therapeutics Losec/Prilosec and Nexium
Revenue (2015) US$ 23,641 million
Source: Annual Reports, Investor Presentations,Primary Interviews andScalar Market Research Analysis
8.1.2 Key Strategies
8.1.2.1 Strong research and development activities
AstraZeneca is one of the key leaders for the global gastrointestinal drugs market.
The company is aggressively focusing on developing novel gastrointestinal
therapeutics for the treatment of conditions such as ulcerative colitis, irritable bowel
syndrome and Crohn’s diseases. In 2015, the company spent US$ 5,997 million for
research and development activities, up 7% as compared to the previous year. The
company aimed to develop new medicines notably in the segment of diabetes and
gastrointestinal diseases.
8.1.2.2 Novel therapeutics in company’s product offering
Owing to the strong research and development focus on gastrointestinal disease
segment, the company has developed novel therapeutics which has shown high
efficacy and safety for the treatment of GIT disorders. For example, the company
offers three gastrointestinal drugs such as Entocort (budesonide), Losec/Prilosec
(omeprazole) and Nexium (esomeprazole magnesium). These drugs are used for the
treatment and cure of GIT problems such as inflammatory bowel disease and acid
related disorders.
SAM
PLE

27. 49
8.1.3 Recent Developments
 Pfizer acquired the exclusive global rights to market AstraZeneca’s Nexium
for OTC indications worldwide in 2012, and launched OTC Nexium 20mg in
the US and Europe in 2014.
 In November 2015, the company entered into an agreement with Perrigo
Company plc for the divestment of US rights to Entocort, a gastroenterology
medicine for patients with mild to moderate Crohn’s disease. Under this
agreement, Perrigo acquired the right to sell Entocort capsules
SAM
PLE

28. 62
10 Appendix
10.1 Acronyms
Table 42. List of Acronyms
Acronym Expansion
IBS-D Irritable Bowel Syndrome with Diarrhea
H. pylori Helicobacter Pylori
GIT Disease Gastrointestinal Disease
U.S. FDA U.S. Food and Drug Administration
DDW Digestive Disease Week
Source: Scalar Market Research Analysis
SAM
PLE